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-Catenin is the nuclear effector of the Wnt signal-
ing cascade. The mechanism by which nuclear ac-
tivity of 
 
 
 
-catenin is regulated is not well deﬁned.
Therefore, we used the nuclear marker RanGTP to screen
for novel nuclear 
 
 
 
-catenin binding proteins. We identi-
ﬁed a cofactor of chromosome region maintenance 1
(CRM1)–mediated nuclear export, Ran binding protein 3
(RanBP3), as a novel 
 
 
 
-catenin–interacting protein that
binds directly to 
 
 
 
-catenin in a RanGTP-stimulated man-
ner. RanBP3 inhibits 
 
 
 
-catenin–mediated transcriptional
activation in both Wnt1- and 
 
 
 
-catenin–stimulated hu-
man cells. In 
 
Xenopus laevis 
 
embryos, RanBP3 interferes
 
 
with 
 
 
 
-catenin–induced dorsoventral axis formation.
Furthermore, RanBP3 depletion stimulates the Wnt path-
way in both human cells and 
 
Drosophila melanogaster
 
embryos. In human cells, this is accompanied by an in-
crease of dephosphorylated 
 
 
 
-catenin in the nucleus. Con-
versely, overexpression of RanBP3 leads to a shift of active
 
 
 
-catenin toward the cytoplasm. Modulation of 
 
 
 
-catenin
activity and localization by RanBP3 is independent of ade-
nomatous polyposis coli protein and CRM1. We conclude
that RanBP3 is a direct export enhancer for 
 
 
 
-catenin,
independent of its role as a CRM1-associated nuclear
export cofactor.
 
Introduction
 
The Wnt signaling pathway regulates a variety of processes
during homeostasis and development, including cellular prolif-
eration, cell fate decision, axis formation, and organ develop-
ment (Nusse, 1999). Deregulation of the pathway is implicated
in many human cancers (Polakis, 2000). The key effector protein
of the Wnt pathway is the transcriptional activator 
 
 
 
-catenin.
Cytoplasmic 
 
 
 
-catenin is efficiently trapped in a multiprotein
complex containing adenomatous polyposis coli (APC; Groden
et al., 1991; Kinzler et al., 1991), Axin (Zeng et al., 1997; Beh-
rens et al., 1998), and glycogen synthase kinase 3
 
 
 
 (GSK3
 
 
 
;
He et al., 1995). In the absence of a Wnt signal, this complex
rapidly phosphorylates 
 
 
 
-catenin, targeting it for degradation
(Hart et al., 1998; Ikeda et al., 1998; Itoh et al., 1998; Sakanaka
et al., 1998). Wnt binding to the Frizzled/LRP (low-density lipo-
protein receptor–related protein) receptors results in inhibition
of the APC–Axin–GSK3
 
 
 
 complex by activation of Dishev-
elled (Boutros and Mlodzik, 1999; Wharton, 2003) and by re-
cruitment of Axin to the plasma membrane by LRP (Mao et al.,
2001; Tolwinski et al., 2003). This results in an increase in
nonphosphorylated 
 
 
 
-catenin that forms active transcriptional
complexes in the nucleus with T cell factor (TCF)/lymphocyte
enhancer binding factor (LEF) transcription factors (Behrens et
al., 1996; Molenaar et al., 1996; Staal et al., 2002).
Nuclear activity of 
 
 
 
-catenin is regulated by several
mechanisms. In the absence of a Wnt signal, TCF proteins oc-
cupy and repress promoters of their target genes by recruiting
repressor proteins like Groucho, CtBP (COOH-terminal bind-
ing protein), and histone deacetylases (Cavallo et al., 1998; Le-
vanon et al., 1998; Roose et al., 1998; Waltzer and Bienz,
1998; Brannon et al., 1999; Chen et al., 1999). Interaction of
 
 
 
-catenin with TCF/LEF transcription factors results in activa-
tion of these genes. BCL-9/Legless and Pygopus have been
shown to be essential components of the 
 
 
 
-catenin–TCF tran-
scription complexes (Kramps et al., 2002; Parker et al., 2002;
Thompson et al., 2002). 
 
 
 
-Catenin also interacts with chromatin
remodeling and histone modification proteins such as Brg1
(Brahma-related gene 1) and CBP (CREB binding protein)/
p300 to promote target gene activation (Hecht and Kemler,
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2000; Takemaru and Moon, 2000; Barker et al., 2001). Further-
more, ICAT (inhibitor of 
 
 
 
-catenin and TCF4) and Chibby are
identified as nuclear proteins that repress Wnt signaling by
competing with TCF for binding to 
 
 
 
-catenin (Tago et al.,
2000; Takemaru et al., 2003).
In this study, we aimed to identify new modulators of
 
 
 
-catenin in the nucleus. We used the nuclear marker RanGTP
to select for nuclear factors that directly bind 
 
 
 
-catenin and
identified Ran binding protein 3 (RanBP3). We show that
RanBP3 inhibits 
 
 
 
-catenin–TCF4–mediated transactivation in
human cell lines by relocalization of active 
 
 
 
-catenin from the
nucleus to the cytoplasm. In addition, we show that RanBP3
causes ventralization and inhibits 
 
 
 
-catenin–induced double
axis formation in 
 
Xenopus laevis 
 
embryos. Loss of 
 
Drosophila
melanogaster 
 
RanBP3 results in cuticle defects and expands
the Engrailed protein expression domain. We conclude that
RanBP3 functions as a novel type of inhibitor of 
 
 
 
-catenin and
identify its gene as a candidate human tumor suppressor in the
commonly deleted chromosomal region 19p13.3.
 
Results
 
RanBP3 interacts directly with 
 
 
 
-catenin 
in a RanGTP-stimulated way
 
To study the interaction between 
 
 
 
-catenin and nuclear trans-
port factors, we used GST-tagged 
 
 
 
-catenin to pull down inter-
acting proteins from 
 
X. laevis 
 
egg extracts. Interacting proteins
were initially analyzed by Western blot using mAb414, which
recognizes a phenylalanine glycine (FG)–rich epitope present
in multiple nucleoporins. FG repeat–containing nucleoporins
Nup62, Nup153, and Nup358 were specifically bound by full-
length 
 
 
 
-catenin and by the central armadillo (ARM) repeat
region (unpublished data). Interestingly, we found a strong
interaction between 
 
 
 
-catenin and two unknown proteins of
 
 
 
80 and 90 kD that were recognized by mAb414 (Fig. 1 A, lanes
3 and 4). These proteins interacted with full-length 
 
 
 
-catenin and
to a lesser extent with the ARM repeats (ARM 1–12). The
mAb414 reactivity indicated that these two proteins contained
FG repeats. Two isoforms of RanBP3 stood out as possible
candidates for these two unknown proteins because they con-
tain FG repeats and have the correct sizes. Indeed, recombinant
human RanBP3-a comigrated with the p90 protein and was
recognized by mAb414 (Fig. 1 A, lane 5). To confirm that
RanBP3 was one of these new 
 
 
 
-catenin–interacting proteins,
we repeated the pull-down experiment using HeLa nuclear ex-
tracts and an mAb recognizing human RanBP3. The b isoform
of RanBP3 was more abundant in HeLa nuclear extracts
and copurified with GST-tagged full-length and the ARM re-
peats of 
 
 
 
-catenin (Fig. 1 B). To mimic nuclear conditions, 2
 
 
 
M of a nonhydrolysable mutant of the small GTPase Ran
(RanQ69L-GTP) was added, resulting in increased interaction
between 
 
 
 
-catenin and RanBP3 (Fig. 1 B, lanes 2 and 4). In the
presence of RanQ69L-GTP, the less abundant a isoform of human
RanBP3 also bound to full-length 
 
 
 
-catenin (Fig. 1 B, lane 2).
To investigate whether the binding between 
 
 
 
-catenin
and RanBP3 was direct, we performed pull-down assays with
GST-tagged 
 
 
 
-catenin and recombinant RanBP3. Human
RanBP3-b interacted directly with GST–
 
 
 
-catenin, with opti-
mum binding at 0.5 
 
 
 
M RanBP3 (Fig. 1 C, lane 3). These bind-
ing characteristics resemble the interaction of RanBP3 with
chromosome region maintenance 1 (CRM1), which shows op-
timal binding at 0.2 
 
 
 
M RanBP3 (Englmeier et al., 2001).
Furthermore, we used a RanBP3 mutant that cannot bind to
RanGTP because of a point mutation in its RanGTP binding
domain (RanBP3 “wv” mutant; Englmeier et al., 2001). This
mutant interacted only very weakly with 
 
 
 
-catenin and lost its
ability to bind at an optimum concentration (Fig. 1 C, lanes 5–7).
These data suggest that RanGTP increases the affinity of
RanBP3 for 
 
 
 
-catenin. To confirm the RanGTP dependency,
RanBP3 was bound to 
 
 
 
-catenin columns at the optimal con-
centration of 0.5 
 
 
 
M in the presence of RanGTP and eluted in
either the absence or presence of the recombinant Ran cofac-
tors RanBP1 and RanGAP (Fig. 1 C, lanes 8–11). Although
virtually no RanBP3 was eluted with buffer only, significant
amounts were detected after elution in the presence of 0.5 
 
 
 
M
RanBP1, 0.2 
 
 
 
M RanGAP, or a combination of these.
 
RanBP3 inhibits transcription of a 
TCF-responsive reporter
 
Wnt signaling ultimately results in the stabilization of 
 
 
 
-catenin,
which forms active transcriptional regulation complexes with
transcription factors of the TCF/LEF family. A well-estab-
lished functional readout of Wnt signaling makes use of TCF-
responsive luciferase reporter constructs (Korinek et al., 1997).
Figure 1. Identification of RanBP3 as an interaction partner of  -catenin.
(A) Pull-down experiment using immobilized GST (lane 2), GST-tagged
 -catenin ARM repeats 1–12 (lane 3), and full-length  -catenin (lane 4)
incubated with X. laevis egg extract (input; lane 1). Bound proteins were
analyzed by Western blot using mAb414 recognizing a subset of nucleo-
porins. Two unknown proteins, p80 and p90, are marked with arrows. (B)
Identification of p80 and p90 as the b and a isoforms of RanBP3. Pull-
down experiment as in A, incubated with HeLa nuclear extracts and ana-
lyzed using RanBP3 antibody. (C) RanBP3 binds directly to  -catenin.
GST-tagged full-length  -catenin (lanes 2–11) was incubated with 2  M
RanGTP and 0.2  M (lanes 2 and 5), 0.5  M (lanes 3, 6, and 8–11), or
2.0  M (lanes 4 and 7) wt (lanes 2–4 and 8–11) or wv mutant (lanes 5–7)
RanBP3-b. Bound proteins were eluted as indicated above the lanes and
visualized with silver (lanes 1–7) or Coomassie (lanes 8–11) staining. 
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To test the functional relevance of the interaction between
 
 
 
-catenin and RanBP3, we transfected human embryonic kid-
ney (HEK) 293 cells with reporter constructs that contain either
three optimal TCF binding sites (TCF optimal promoter
[TOP]) or three mutated binding sites (fake optimal promoter
[FOP]). Transfection of a Wnt1 plasmid resulted in a strong ac-
tivation of the TOP reporter but not of the FOP control (Fig. 2 B).
Cotransfection of increasing amounts of RanBP3 repressed
Wnt1/
 
 
 
-catenin transactivation dose dependently (Fig. 2 B).
A mutant of RanBP3 that cannot interact with RanGTP and
binds 
 
 
 
-catenin with less affinity (Fig. 1 C) was less active than
wild-type (wt) RanBP3 (Fig. 2 B). To investigate whether
RanBP3 inhibits Wnt signaling downstream or upstream of
 
 
 
-catenin, we mimicked Wnt signaling in HEK293 cells by ex-
pressing 
 
 
 
-catenin. RanBP3 could still specifically inhibit acti-
vation of the TOP reporter (Fig. 2 C), whereas the RanBP3
wv mutant was less effective. These experiments show that
RanBP3 inhibits TCF-dependent transcription by acting on ei-
ther 
 
 
 
-catenin itself or regulators downstream of 
 
 
 
-catenin. We
confirmed that the expression levels of our wt and wv mutant
RanBP3 constructs were equal by analyzing cell lysates from
transfected HEK293 cells on Western blot (Fig. 2 A).
The interaction of recombinant 
 
 
 
-catenin with RanBP3
(Fig. 1 C) implies that RanBP3 can bind NH
 
2
 
-terminally un-
phosphorylated 
 
 
 
-catenin, which is thought to be the signaling-
competent form of the protein. To determine whether this is
the case in vivo, we used a 
 
 
 
-catenin mutant that contains ala-
nines in all four NH
 
2
 
-terminal GSK3
 
 
 
 phosphorylation sites
(
 
 
 
-catenin
 
 
 
GSK3
 
 
 
; Barth et al., 1999) and therefore is constitu-
tively active. This mutant stimulated expression of the TCF
reporter to levels that were two to three times higher than wt
 
 
 
-catenin (unpublished data). Coexpression of wt RanBP3 leads
to a significant reduction in transactivation by 
 
 
 
-catenin
 
 
 
GSK3
 
 
 
(Fig. 2 D). Again, the RanBP3 RanGTP-binding mutant was less
able to repress 
 
 
 
-catenin
 
 
 
GSK3
 
 
 
–mediated transactivation.
To address whether RanBP3 could also affect expression
of endogenous target genes of 
 
 
 
-catenin–TCF, we expressed
RanBP3 in human colon carcinoma cell line HCT116. This cell
line harbors an activating mutation in 
 
 
 
-catenin (
 
 
 
45 catenin)
and therefore expresses increased levels of the target gene c-myc
(He et al., 1998). Expression of wt RanBP3 decreased c-Myc
protein levels compared with control cells (Fig. 2 E, lanes 2
and 3). Although expressed in higher levels, the wv mutant
RanBP3 was less capable of decreasing c-Myc levels.
Reduction of RanBP3 results in 
increased transactivation of a 
TCF-responsive reporter
In addition to studying the effects of RanBP3 overexpression,
we studied the effects of RanBP3 depletion. We expressed
short hairpin RNAs (shRNAs) directed against unique parts of
RanBP3 that are present in all isoforms of RanBP3. We ob-
tained several shRNA RanBP3 constructs that down-regulate
RanBP3 protein levels in HEK293 cells (Fig. 3 A).
When we coexpressed Wnt1 and RanBP3 shRNAs, we
observed significant increases in TCF/LEF reporter activity
compared with the GFP–RNA interference (RNAi) control
(Fig. 3 B). To determine whether RanBP3 depletion also acts
on NH2-terminally dephosphorylated  -catenin, we cotrans-
fected  -catenin
 GSK3  with anti–RanBP3 shRNA expression
constructs (Fig. 3 C). Reduction of RanBP3 increased reporter
activity, confirming that RanBP3 can act on the NH2-terminally
dephosphorylated or “activated” form of  -catenin. In the ab-
sence of Wnt signaling, depletion of RanBP3 did not result in
increased reporter activity (Fig. 3 D), arguing for a specific ef-
fect on  -catenin. The direct binding of RanBP3 to  -catenin
that we observed (Fig. 1 C) indicated that RanBP3 may act on
Figure 2. Expression of RanBP3 inhibits  -catenin/TCF–mediated tran-
scriptional activation. (A) Wt and wv mutant RanBP3 are expressed at
equal levels. HEK293 cells were transfected with the indicated constructs
(ng), and lysates were analyzed 48 h after transfection by Western blot
with the indicated antibodies. (B) RanBP3 represses Wnt1-induced  -cate-
nin/TCF–mediated transcriptional activation dose dependently. HEK293
cells were transfected with TOP (black bars) or the control FOP (gray
bars), Wnt1, and decreasing amounts of RanBP3 wt or wv mutant as indi-
cated (ng), and luciferase activity was measured after 48 h. (C and D)
RanBP3 represses transcriptional activation induced by wt  -catenin (C) or
 GSK3– -catenin (D). HEK293 cells were transfected with the indicated
constructs, and luciferase activity was measured 48 h after transfection.
In all experiments, normalized relative luciferase values are shown as
corrected with pRL-CMV Renilla. Bars represent SEMs of independent ex-
periments. (E) RanBP3 inhibits the expression of the endogenous Wnt
target c-Myc. HCT116 colon carcinoma cells expressing  45– -catenin
were transfected with GFP and  -galactosidase, RanBP3 wt, or mutant
plasmids. 2 d after transfection, GFP-positive cells were sorted using
flow cytometry, lysed in sample buffer, and analyzed by Western blot
using the indicated antibodies.JCB • VOLUME 171 • NUMBER 5 • 2005 788
the Wnt signaling pathway independently of CRM1, which has
been reported to play a role in  -catenin nuclear export via in-
teraction with APC (Henderson, 2000; Neufeld et al., 2000;
Rosin-Arbesfeld et al., 2000). Increased expression of CRM1 is
able to compensate for reduction of CRM1 nuclear export at re-
duced RanBP3 levels (Taura et al., 1998; Noguchi et al., 1999).
Therefore, we expressed CRM1 in combination with Wnt1 and
RanBP3 shRNAs. As shown in Fig. 3 D, CRM1 overexpres-
sion did not reverse the effects of RanBP3 depletion, indicating
that the mechanism by which Wnt signaling is modulated by
RanBP3 is independent of CRM1-mediated nuclear export of
 -catenin.
RanBP3 down-regulates 
 -catenin–mediated transactivation 
independently of APC
To further address the question of whether RanBP3 represses
 -catenin transcriptional activation by stimulating export of
 -catenin via the APC–CRM1 pathway, we expressed RanBP3
in human colorectal cancer cell lines that express COOH-terminal
truncations of APC. First, we tested DLD1 cells, which express
APC
1–1417, which retains some  -catenin binding sites but lacks
all COOH-terminal nuclear export signals (NESs), the most
highly conserved APC NESs in evolution. As shown in Fig. 4 A,
 -catenin/TCF activity is already high in these cells. Expres-
sion of a RanBP3 wt or wv mutant could still dose-dependently
down-regulate transcriptional activity, with the mutant again
being a less potent inhibitor (Fig. 4 A). Because APC in DLD1
cells can still bind to  -catenin and NESs have also been re-
ported in the NH2 terminus of APC, we repeated the experi-
ment in COLO320 cells. These cells express a very short
APC truncation (1–811) that lacks all  -catenin binding
sites.  -catenin/TCF activity was much higher in these cells
than in DLD1 cells, a finding that correlates with the severity
of the APC mutation (Fig. 4 B; Rosin-Arbesfeld et al., 2003).
Nevertheless, transfection of the RanBP3 expression constructs
caused a significant down-regulation of transcription (Fig. 4 B).
Therefore, the mechanism by which RanBP3 inhibits  -catenin
is independent of a nuclear export function of APC.
RanBP3 influences subcellular 
localization of active  -catenin
To study the mechanism by which RanBP3 inhibits Wnt sig-
naling, we tested the possibility that RanBP3 influences the
stability of  -catenin. We transfected HEK293 cells with or
without Wnt1 in combination with shRNA constructs. Total
 -catenin levels were virtually unchanged after expression of
Wnt1 alone or in combination with shRNA against RanBP3
(Fig. 5 A). When the same blot was probed with anti–active
 -catenin, recognizing NH2-terminally dephosphorylated  -cat-
enin, we observed an increase in Wnt1-transfected cells but no
effects on RanBP3 (Fig. 5 A). From this data, we conclude that
RanBP3 depletion does not affect  -catenin degradation.
We next prepared nuclear and cytoplasmic extracts from
HEK293 cells transfected with or without Wnt1 and RNAi
against GFP or RanBP3. Total  -catenin was mostly detected
in the cytosol fraction (Fig. 5 B). No change in total  -catenin
levels was observed in the nucleus or cytoplasm after transfec-
tion with Wnt1 (Fig. 5 B, lane 2) or treatment with RNAi (lanes
3 and 4). When we stained for active  -catenin, a clear increase
Figure 3. Reduction of RanBP3 by RNAi results in
increased   -catenin/TCF–mediated transcription
activation.  (A) Western blot showing that different
shRNAs against RanBP3 reduce RanBP3 protein levels
in HEK293 cells. Cells were transfected with shRNAs,
and pHA262-PUR was cotransfected to introduce puro-
mycin resistance. 24 h after transfection, cells were
grown on puromycin medium for 48 h and cell lysates
were prepared and analyzed on Western blot with
the indicated antibodies. (B) RNAi against RanBP3
increases Wnt1-induced  -catenin/TCF–mediated
transcription. HEK293 cells were transfected with
the indicated constructs, and activity of TOP (black
bars) and FOP (gray bars) was measured 72 h after
transfection. Error bars represent SDs of technical rep-
licates of a representative experiment. (C) RNAi
against RanBP3 increases  -catenin/TCF–driven tran-
scription in HEK293 cells that transiently express an
active form of  -catenin ( GSK3– -catenin). Cells
were transfected with indicated constructs, and lu-
ciferase activity was measured after 72 h. (D) Coex-
pression of CRM1 with RanBP3 shRNA constructs
does not affect  -catenin/TCF–mediated transcription
in Wnt1-transfected cells. HEK293 cells were trans-
fected with the indicated constructs, and 72 h after
transfection luciferase activity was measured. For all
experiments, relative luciferase levels are shown as
corrected with CMV-Renilla-luc. Error bars in C and D
represent SEMs of independent experiments. ENHANCED NUCLEAR EXPORT OF  -CATENIN BY RANBP3 • HENDRIKSEN ET AL. 789
was evident after stimulation with Wnt1 (Fig. 5 B, lane 2).
Interestingly, when cells were transfected with RNAi against
RanBP3, active  -catenin significantly increased in the nuclear
fraction and decreased in the cytosolic fraction (Fig. 5 B, lane 4),
suggesting that RanBP3 relocates active  -catenin from the nu-
cleus to the cytoplasm. As controls for fractionation, TCF4 was
used as a nuclear marker and  -tubulin as a cytoplasmic marker.
Both proteins were strongly enriched in the proper compartments.
Nuclear/cytoplasmic fractionation data does not always
reflect the subcellular localization in living cells because pools
of proteins that are not tightly bound to nuclear or cytoplasmic
structures and are relatively small may leak through nuclear
pore complexes of permeabilized cells. We therefore assayed
the effect of RanBP3 overexpression on active  -catenin in situ
using the anti–active  -catenin antibody. In our hands, this an-
tibody did not visualize endogenous dephosphorylated  -catenin
in Wnt1-transfected HEK293 cells (unpublished data). We
therefore tested two colon carcinoma cell lines (SW480 and
DLD1) that have a constitutively activated  -catenin because
of a mutation in APC (Rosin-Arbesfeld et al., 2003). In
SW480, but not in DLD1, the anti–dephosphorylated  -catenin
antibody recognizes a clear nuclear signal above background
(Fig. 6, A and C). The presence of this signal correlates with
the exceptionally high  -catenin activity as measured in lu-
ciferase assays (Fig. 6 D), i.e.,  30-fold higher than in DLD1.
Importantly, RanBP3 overexpression leads to a clear reduction
of active  -catenin signal from the SW480 nuclei (Fig. 6 A) but
has no influence on total  -catenin localization (Fig. 6 B). This
indicates that, even in the extremely active SW480 cell line,
only a very small proportion of total  -catenin is properly de-
phosphorylated and active, and that this is the pool RanBP3
acts on.
RanBP3 enhances nuclear export of 
active  -catenin independently of CRM1
Reduction of active nuclear  -catenin by RanBP3 in SW480
cells was not accompanied by an increase in cytoplasmic sig-
nal, raising the question of whether RanBP3 induces enhanced
nuclear export of active  -catenin or its increased phosphorylation.
However, enhanced nuclear export would result in dilution in a
Figure 4. RanBP3 antagonizes Wnt/ -catenin transactivation in APC-
mutated colon carcinoma cells. Luciferase assay showing that RanBP3
inhibits  -catenin–mediated transactivation in colon carcinoma cell lines
DLD1 and COLO320. (A) APC type I truncated human colon carcinoma
cell line DLD1 (APC 1–1417) was transfected with luciferase reporter
constructs and increasing amounts of RanBP3 expression constructs as
indicated. DLD1 cells express a truncated APC protein that lacks all its
COOH-terminal NESs. (B) Luciferase reporter assay as in A, performed in
the APC type I truncated human colon carcinoma cell line COLO320 (APC
1–811). These cells express a short APC protein that lacks all  -catenin
binding and regulatory sites. Relative luciferase activity was measured 48 h
after transfection. Error bars show SDs of a representative experiment.
Figure 5. Depletion of RanBP3 results in nuclear accumulation of active
 -catenin. (A) Depletion of RanBP3 does not alter the levels of both total
and active dephosphorylated  -catenin. HEK293 cells were transfected with
or without Wnt1 and shRNA constructs against GFP or RanBP3. 72 h after
transfection, whole cell lysates were analyzed by Western blot with the
indicated antibodies. (B) RNAi against RanBP3 results in increased levels
of active  -catenin in the nucleus. HEK293 cells were transfected with the
indicated constructs, and 72 h after transfection, nuclear and cytoplasmic
extracts were prepared and analyzed by Western blot. TCF4 and tubulin
staining are shown as markers for purity of the nuclear and cytoplasmic
fractions. As a loading control in the nuclear fractions, TCF4 and a non-
specific reaction of the antibody recognizing active  -catenin are shown.JCB • VOLUME 171 • NUMBER 5 • 2005 790
cytoplasmic volume that is  10-fold larger than that of the
nucleus, precluding detection by the anti–dephosphorylated
 -catenin antibody. To discriminate between the two possibili-
ties, we mimicked the active state of  -catenin using a mono-
meric red fluorescent protein (mRFP)–tagged, constitutively
active form of  -catenin, the previously used  -catenin
 GSK3 .
To determine whether this fusion protein was biologically ac-
tive, we performed a TCF reporter assay in the malignant me-
sothelioma cell line NCI-H28, which carries a homozygous
deletion of the  -catenin gene (Calvo et al., 2000). This pre-
vented possible activating effects of this mutant on endogenous
 -catenin. mRFP– -catenin
 GSK3  activated the very low en-
dogenous TCF activity of these cells to a great extent (Fig. 7 B).
We next compared the subcellular localization of this protein in
the presence or absence of exogenous RanBP3 (Fig. 7 A). Care
was taken to record cells of similarly low expression levels
(Fig. 7 C). In control cells, more mRFP– -catenin
 GSK3  was
present in the nuclei than in the cytoplasm (median nuclear to
cytoplasmic ratio of 1.38, n   37). In contrast, cells expressing
exogenous RanBP3 showed higher cytoplasmic than nuclear
mRFP– -catenin
 GSK3  levels (median nuclear to cytoplasmic
ratio of 0.77, n   41). Importantly, addition of 50 mM of the
CRM1 inhibitor leptomycin B (LMB; Wolff et al., 1997) did
not significantly change the effect of RanBP3 (median nuclear
to cytoplasmic ratio of 0.80, n     52), even though pho-
tobleaching experiments show that mRFP– -catenin
 GSK3  rap-
idly shuttles between the nucleus and cytoplasm (unpublished
data). Identical LMB treatment dramatically relocalized the
NES-containing reporter protein Rev(1.4)-NES-GFP (Henderson
and Eleftheriou, 2000) to the nucleus (Fig. 6 D). We conclude
that RanBP3 enhances nuclear export of active  -catenin and
that this export is independent of CRM1. To confirm that en-
dogenous activated  -catenin relocalizes from the nucleus to
the cytoplasm upon overexpression of RanBP3 in HEK293
cells, we transfected these cells with Wnt1 and RanBP3. Indeed,
we observed increased active  -catenin levels in both nuclear
and cytoplasmic fractions, with the nuclear pool being more
sensitive than the cytoplasmic pool to RanBP3 overexpression
(Fig. 7 E). The decrease in cytoplasmic active  -catenin is con-
sistent with increased nuclear export of  -catenin and subse-
quent degradation in the cytoplasm.
RanBP3 suppresses dorsal-ventral axis 
formation in X. laevis embryos
To study the role of RanBP3 in Wnt signaling in a physiologi-
cal context, we used an X. laevis axis duplication assay. During
X. laevis embryonic development, Wnt signaling determines
patterning along the dorsal-ventral axis. Ectopic ventral injec-
tion of  -catenin mRNA in four-cell embryos resulted in clear
axis duplication (Fig. 8, A and B). The majority (75%) of the
embryos showed a complete duplication of the dorsal-ventral
axis. 22% of the embryos showed a partial duplication, i.e., a
secondary axis without duplicated cement gland. However,
coinjection of  -catenin mRNA with RanBP3 mRNA resulted
in a strong suppression of the double axis phenotype in the ma-
jority (63%) of the embryos. Few partial or very partial second-
ary axis phenotypes (24 and 13%, respectively) were observed
in these embryos (Fig. 6 B). We also coinjected  -catenin
mRNA with mRNA of the RanBP3 wv mutant that is defective
in RanGTP binding. This mutant suppressed the double axis
phenotype but was not as potent of an inhibitor as the wt
RanBP3 (Fig. 8, A and B; P   4e-8). This data correlates with
our findings that this RanBP3 mutant binds  -catenin with less
affinity (Fig. 1) and that it is less active in repressing the tran-
scriptional activity of a TCF reporter gene in human cell lines
(Figs. 2 and 4). If RanBP3 is an inhibitor of nuclear  -catenin
Figure 6. RanBP3 induces specific depletion
of endogenous nuclear active  -catenin.
SW480 (A and B) or DLD1 (C) colon carci-
noma cells were transfected with RanBP3 ex-
pression plasmids and stained after 45 h for
dephosphorylated  -catenin (A and C) or total
 -catenin (B). RanBP3 expression was visual-
ized in the same cells using a RanBP3 poly-
clonal (A and C) or mAb. (D) Luciferase reporter
assay as in Figs. 2–4 measuring relative  -cat-
enin  activity. Cells were transfected as in A
and C. Error bars represent SDs of technical
replicates. ENHANCED NUCLEAR EXPORT OF  -CATENIN BY RANBP3 • HENDRIKSEN ET AL. 791
function, dorsal injection of RanBP3 mRNA is expected to re-
sult in ventralization of the embryo. We therefore injected four-
cell embryos dorsally with either RanBP3 or control mRNA
and scored ventralization after 3 d of development using the
dorsoanterior index (DAI; Kao and Elinson, 1988). Mild to
severe ventralization was observed (DAI 1–4) in 80% of
RanBP3-injected embryos (Fig. 8 C), whereas  10% of control-
injected embryos showed these phenotypes. Complete ventraliza-
tion (DAI 0) was not observed. An important direct downstream
target of dorsal nuclear  -catenin activity is the early Wnt-
inducible homeobox gene Siamois (Brannon et al., 1997). We
therefore tested to determine whether expression levels of this
gene were reduced in the RanBP3-injected embryos by RT-PCR.
In four independent experiments, we detected an approxi-
mately twofold decrease in Siamois levels in late stage 9 em-
bryos (Fig. 8, D and E). This decrease is rather mild, consistent
with the incomplete ventralization phenotypes observed. Based
on these findings, we conclude that RanBP3 not only is a re-
pressor of Wnt signaling in human cell lines but also functions
as an antagonist of Wnt signaling in X. laevis embryos.
Loss of function of ranbp3 results in a 
naked cuticle phenotype in 
D. melanogaster
Wnt signaling is highly conserved between different species.
We identified the D. melanogaster RanBP3 homologue and
used RNAi to study its role in D. melanogaster development. At
the end of embryogenesis, the ventral epidermis is covered by a
cuticle that is built up by a repeating pattern of naked cuticle
and denticles (Fig. 9 A). Wingless (Wg; D. melanogaster Wnt)
signaling increases levels of ARM ( -catenin) that specifies the
fate of epidermal cells responsible for secreting naked cuticle.
Therefore, loss of wg expression results in an embryo that is
covered with denticles lacking naked cuticle (Nusslein-Volhard
and Wieschaus, 1980) and overexpression of wg results in a na-
ked cuticle embryo (Noordermeer et al., 1992). Likewise, loss
of an inhibitor of Wnt signaling also results in naked cuticle em-
bryos as shown by RNAi against Daxin (Willert et al., 1999).
As a control, we injected embryos with  -galactosidase double-
stranded RNA (dsRNA) and observed that the majority (97%)
developed into larvae that were indistinguishable from nonin-
jected wt larvae (Fig. 9 A). 3% of these control embryos showed
some very weak effects on denticle belt formation (Fig. 9 G).
RNAi against Daxin resulted in a significant increase in naked
cuticle phenotype in 24% of the Daxin dsRNA–injected em-
bryos (Fig. 9 G), with phenotypes varying from partial loss of
denticles to completely naked embryos (Fig. 9, B and C). Injec-
tion of dsRNA against the D. melanogaster RanBP3 caused a
partial or complete transformation of denticles into naked cuticle
in 14% of the embryos (Fig. 9, D–F). The most severe pheno-
types of the RanBP3 RNAi embryos showed deformation of both
the head and spiracles (Fig. 9 F), resembling Daxin RNAi (Fig.
9 C). In addition, almost all RanBP3 RNAi embryos showing a
strong naked cuticle phenotype were shorter than the embryos in-
jected with Daxin dsRNA. To confirm that the RanBP3 dsRNA
injections resulted in decreased RanBP3 levels, we performed
RT-PCR on buffer and RanBP3 dsRNA–injected embryos.
Fig. 9 H shows that RanBP3 mRNA levels were indeed de-
creased in RanBP3 dsRNA–injected embryos, whereas RP49
control mRNA levels remained unaffected. We then assayed the
effects of RanBP3 dsRNA injection on wg target gene induction.
For this, stage 10 RanBP3 or Daxin dsRNA–injected embryos
were stained with anti-Engrailed antibody. Normal engrailed
Figure 7. RanBP3 enhances nuclear export of active  -catenin indepen-
dently of CRM1. (A and C) Effect of RanBP3 on mRFP– GSK– -catenin nu-
cleocytoplasmic distribution in HEK293 cells in the presence or absence of
50 nM LMB for 3 h. (A) Box plot showing the distribution of nuclear/cyto-
plasmic ratios of mRFP– GSK– -catenin of two independent experiments.
P values are according to Mann-Whitney tests. Representative mRFP fluo-
rescence images are shown in C. Highlighted nuclear borders are drawn
on the basis of accompanying phase-contrast images. (B) Functionality of
mRFP– GSK3– -catenin. NCI-H28 cells (lacking endogenous  -catenin)
were transfected with indicated constructs, and 48 h after transfection,
luciferase activity was measured. Relative luciferase levels as corrected for
transfection efficiency (Renilla luciferase activity) are shown. Error bars
represent SDs. (D) Representative fluorescence images of HEK293 cells ex-
pressing GFP-Rev(1.4)-NES in the presence or absence of 50 nM LMB for
3 h. (E and F) Endogenous activated  -catenin relocalizes from the nucleus
to the cytoplasm upon overexpression of RanBP3. HEK293 cells were
transfected with Wnt and RanBP3 as indicated together with TOP-TK-luc
and Renilla transcription reporter plasmids and fractionated after 48 h as
in Fig. 5. Localization of active  -catenin was monitored using anti–active
 -catenin antibody. Amounts of protein loaded were normalized on trans-
fection efficiency (Renilla luciferase activity). Normalized  -catenin/TCF–
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expression is present in segmental stripes that are two cells wide
(Fig. 9 I, left). Removal of the Wnt signaling inhibitor Daxin by
dsRNA injection resulted in a broader Engrailed expression
pattern that extended from two to four rows of cells (Fig. 9 I,
middle). In RanBP3 dsRNA–injected embryos, Engrailed ex-
pression expanded by one row of cells (Fig. 9 I, right). These
in vivo data show that removal of RanBP3 leads to a pheno-
type that is associated with Wnt signaling activation, suggesting
that RanBP3 also acts as negative regulator of Wnt signaling in
D. melanogaster.
Discussion
In this study, we identify RanBP3 as a novel inhibitor of Wnt
signaling that acts on  -catenin directly by enhancing nuclear
export of its active form. We show that RanBP3 binds directly
to  -catenin and that the interaction is increased in the presence
of RanGTP. Expression of RanBP3 represses Wnt signaling
both in vitro and in X. laevis embryonic development. Inhibition
of RanBP3 by RNAi causes overactivation of Wnt signaling in
tissue culture cells and in D. melanogaster embryos. In addi-
tion, expression of RanBP3 in human cells specifically reduces
active  -catenin levels in the nucleus and relocates  GSK3–
 -catenin from the nucleus to the cytoplasm, independently
of CRM1.
RanBP3 was originally identified as a nuclear protein that
contains FG repeats and a RanGTP-binding domain (Mueller et
al., 1998). RanBP3 can directly bind the nuclear export re-
ceptor CRM1, stimulating the formation of nuclear export
complexes and increasing the export rate of certain CRM1
substrates (Englmeier et al., 2001; Lindsay et al., 2001). One
mechanism by which RanBP3 could influence  -catenin activ-
ity would therefore be increased nuclear export via the CRM1
pathway. Although the nuclear export mechanisms of  -catenin
are not fully understood, two pathways have been proposed
(Henderson and Fagotto, 2002). In the first,  -catenin exits the
nucleus independently of nuclear export receptors by interacting
directly with proteins of the nuclear pore complex (Eleftheriou
et al., 2001; Wiechens and Fagotto, 2001). In the second path-
way,  -catenin exits the nucleus via the CRM1 pathway, but
Figure 8. RanBP3 rescues  -catenin–induced
double axis formation in X. laevis embryos.
(A) X. laevis embryos were injected ventrally
at the four-cell stage with  -catenin mRNA in
the presence or absence of control  -galactosi-
dase or X. laevis RanBP3-b mRNA. (top) Wt
noninjected embryos. (middle) Double axis phe-
notype as induced by the injection of  -catenin
mRNA. (bottom) Embryos that are rescued
from the double axis phenotype by coexpres-
sion of RanBP3 and  -catenin mRNA. (B)
Quantification of the different phenotypes of
two independent experiments in four catego-
ries: complete secondary axis (with cement
gland), partial secondary axis (i.e., any sec-
ondary axis lacking the cement gland), vesti-
gial axis (very small posterior protrusion or
pigmented line), and normal (only one axis).
P values are according to Pearson’s  
2 test for
count data. (C) Dorsal injection of RanBP3 re-
sults in ventralization of X. laevis embryos.
Four-cell stage embryos were injected dorsally
with RanBP3 or control ( -galactosidase)
mRNA and analyzed 3 d later for ventraliza-
tion using the standardized DAI. This scale
runs from 0 (complete ventralization) to 5 (nor-
mal development). Frequencies are derived
from three independent experiments. P values
as in B. (D) The  -catenin downstream target
siamois is significantly down-regulated in
RanBP3-injected embryos. Embryos were in-
jected as in C and analyzed for siamois or
ornithine decarboxylase (ODC) mRNA using
RT-PCR.  Amplified ethidium bromide–stained
DNA of four experiments was quantified and
normalized to mean signals from  -galactosi-
dase–injected embryos and represented in a
box plot. P values are according to Mann-
Whitney tests. (E) Representative signals from
RT-PCR reactions visualized by ethidium bro-
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because  -catenin does not contain NESs of its own, it uses
binding to APC to exit the nucleus. The APC tumor suppressor
does contain functional NESs and has been shown to be ex-
ported by CRM1 (Henderson, 2000; Neufeld et al., 2000;
Rosin-Arbesfeld et al., 2000). Therefore, RanBP3 could inhibit
 -catenin by stimulating its export via APC and CRM1. How-
ever, four lines of evidence argue against this. First, in a CRM1
export complex, RanBP3 would bind to the complex via
CRM1. Instead, we find that RanBP3 interacts directly with
 -catenin. Second,  -catenin activity is RanBP3 sensitive in
the colon carcinoma cell line COLO320 (Quinn et al., 1979)
that expresses a short type I APC truncation lacking all  -catenin
interaction sites (Rosin-Arbesfeld et al., 2003). We cannot for-
mally exclude the possibility that the neuronal APC-like pro-
tein APC2 (van Es et al., 1999), which is expressed in certain
colon carcinoma cell lines, compensates for the loss of APC.
However, in luciferase reporter assays, CRM1 overexpression
does not reverse stimulation of  -catenin activity caused by de-
pletion of RanBP3. Finally, RanBP3-mediated relocalization of
active  -catenin is insensitive to LMB, a potent CRM1 inhibi-
tor (Wolff et al., 1997). Therefore, we conclude that the mecha-
nism by which RanBP3 inhibits  -catenin is independent of
CRM1 and APC.
It was recently suggested that nuclear  -catenin signaling
is performed mainly by  -catenin dephosphorylated at serine
37 and threonine 41, which are main target sites of GSK3 
(Staal et al., 2002; van Noort et al., 2002). Depletion of
RanBP3 by RNAi specifically increases the amount of dephos-
phorylated   -catenin in nuclear fractions, whereas RanBP3
overexpression has the opposite effect. No concomitant in-
crease, but rather a small decrease, of cytoplasmic endogenous
active  -catenin was observed by overexpression of RanBP3.
We attribute this to cytoplasmic phosphorylation and subse-
quent degradation of wt  -catenin.
Endogenous active  -catenin was visualized in situ, using
the anti–active  -catenin antibody recognizing dephosphory-
lated  -catenin. This was only possible in SW480 colon carci-
noma cells that contain a high level of active  -catenin because
of severely defective APC function (Korinek et al., 1997).
RanBP3 overexpression reduced active  -catenin levels in the
nucleus but had no effect on total  -catenin. This suggests that
only a small proportion of total  -catenin is active in SW480
cells and confirms the specificity of RanBP3 for active  -catenin.
Apparently, absence of proper  -catenin phosphorylation and
degradation is not sufficient for  -catenin to be in an active, de-
phosphorylated state. Also, we infer that the modulation by
Figure 9. Loss of RanBP3 by RNAi results in a naked
cuticle phenotype in D.  melanogaster.  Shown are
dark field images of cuticle preparations of control
( -galactosidase; A), D. melanogaster Daxin (B and C),
and D. melanogaster RanBP3 dsRNA–injected embryos
(D–F). Loss of Daxin and RanBP3 results in increased
Wnt signaling and replacement of denticles by naked
cuticle. Partially naked cuticles (B and D), nearly na-
ked cuticles (E), and naked cuticles (C and F) are
shown. All views are ventral, top is posterior. (G)
Quantification of two representative experiments
showing the frequency of the cuticle phenotype. P val-
ues are calculated as in Fig. 7 B. Note that the contri-
bution of the completely naked phenotype in the
RanBP3 RNAi embryos is relatively high (not de-
picted). (H) RT-PCR showing reduction in RanBP3
mRNA levels in RanBP3 dsRNA–injected embryos.
Embryos were injected as in A, and RNA was ex-
tracted after 15 h of development. RT-PCRs specific
for RanBP3 or control (ribosomal protein RP49) were
performed using nothing (0) or a series of twofold di-
lutions of extracted RNA. (I) Loss of RanBP3 function
by dsRNA injection results in increased expression of
the wg target gene engrailed. Shown are an Engrailed
antibody staining of a buffer-injected embryo (left), a
Daxin dsRNA–injected embryo (middle), and an
RanBP3 dsRNA–injected embryo (right). Note that the
buffer-injected embryo developed until late stage 11,
whereas the Daxin and RanBP3 RNAi embryos shown
are stage 10 embryos, which explains the larger cells
in the former embryo. The number of Engrailed-positive
cell rows between stages 10 and 11 is identical.
Ventral-lateral view is shown, posterior is left.JCB • VOLUME 171 • NUMBER 5 • 2005 794
RanBP3 of  -catenin activity as measured in our luciferase re-
porter assays acts on a small dephosphorylated pool, explaining
why RanBP3 modulates wt and  GSK3– -catenin to a similar
extent (Figs. 2 and 4).
To determine whether RanBP3 enhances  -catenin NH2-
terminal phosphorylation or nuclear export, we have visualized
both nuclear and cytoplasmic distribution of active  -catenin.
For this, we used a fluorescently tagged  -catenin
 GSK3 that is
resistant to NH2-terminal phosphorylation and degradation. As
shown in Fig. 7, RanBP3 causes a clear and significant shift of
 -catenin
 GSK3 from the nucleus to the cytoplasm. We therefore
conclude that RanBP3 directly enhances nuclear export of ac-
tive  -catenin. How does RanBP3 perform this task? Recent
studies have indicated that the interactions of nuclear factors
with chromatin or with each other are dynamic (Dundr et al.,
2002; Phair et al., 2004). This suggests that RanBP3 does not
need to actively remove  -catenin from the TCF/LEF–chromatin
complexes. We therefore favor the possibility that association
with RanBP3 prevents association of active  -catenin with
chromatin and keeps it in a more soluble state. In itself, this
would be sufficient to allow CRM1-independent nuclear exit.
We do not know whether RanBP3 accompanies  -catenin to
the cytoplasm and acts as a true nuclear export factor. The
stimulatory effect of RanGTP on the  -catenin–RanBP3 inter-
action and the consistently weaker inhibitory effects on  -catenin
of a RanBP3 mutant unable to bind RanGTP would argue in fa-
vor of this possibility. Hydrolysis of RanGTP in the cytoplasm
would increase the efficiency of release of  -catenin for subse-
quent interactions with the cytoplasmic interacting proteins,
such as E-cadherin or the APC–Axin–GSK3  complex.
We studied the effect of RanBP3 in X. laevis and D.
melanogaster embryogenesis. Overexpression of the X. laevis
homologue of RanBP3 during early embryogenesis inhibits
 -catenin–dependent dorsoventral axis formation. RNAi of the
D. melanogaster homologue of RanBP3 causes naked cuticle
phenotypes and a broader Engrailed expression domain be-
cause of overactivation of the Wnt signaling pathway. There-
fore, the results obtained in these two model organisms support
the results obtained in cultured human cell lines and indicate
that the inhibitory function of RanBP3 is highly conserved in
metazoan evolution.
Wnt signaling plays an important role in tumor initiation
and progression in a variety of human solid tumors, including
colon carcinomas, hepatocellular carcinomas, and melanomas
(Bienz and Clevers, 2000; Polakis, 2000). As a negative modu-
lator of Wnt signaling, RanBP3 is a novel candidate tumor sup-
pressor protein. Interestingly, the RanBP3 gene is located in
19p13.3, a region that is commonly deleted in several types of
cancer and in which multiple tumor suppressor genes are likely
to be present (Lee et al., 1998; Oesterreich et al., 2001; Tucci et
al., 2001; Yanaihara et al., 2003; Kato et al., 2004; Miyai et al.,
2004; Yang et al., 2004). Further work is required to determine
whether the loss of the RanBP3 gene contributes to these or
other types of cancer.
In conclusion, we have identified an unexpected role for
RanBP3 as a novel inhibitor of Wnt signaling that enhances nu-
clear export of active  -catenin. This function is separate from its
role in CRM1-mediated nuclear export. The structural similarities
between CRM1 and  -catenin suggest that RanBP3 may be a
more general cofactor for nuclear export of ARM repeat proteins.
Materials and methods
Data analysis
Statistical analysis was done using the R software package (R Development
Core Team, 2005).
Reagents
Antibodies used were  -catenin (Transduction Laboratory and Santa Cruz
Biotechnology, Inc.), RanBP3 (Transduction Laboratory and Affinity Bio-
Reagents, Inc.), active  -catenin, TCF4 (Upstate Biotechnology), 414 (Eu-
rogentec/Babco),  -tubulin (European Collection of Cell Cultures), actin
(Oncogene Research Products), and c-Myc (Santa Cruz Biotechnology,
Inc.). The 4D9 anti-Engrailed/invected mAb was a gift from C. Goodman
(University of California, Berkeley, Berkeley, CA; Patel et al., 1989).
Plasmids
The following plasmids were used: GST– -catenin and GST-ARM
(Wiechens and Fagotto, 2001), pET14b-h-RanBP3-b (Mueller et al.,
1998), pET14b-h–RanBP3-b wv mutant (Englmeier et al., 2001), and
pRev(1.4)-RevNES-GFP (Henderson and Eleftheriou, 2000). pQE32-Ran
and pQE32-RanQ69L were gifts from D. Görlich (Center for Molecular
Biology Heidelberg, Heidelberg, Germany). TOP/FOP-Tk, Wnt1, GFP–
 -catenin, and pSUPER plasmid were gifts from H. Clevers (Hubrecht
Laboratory, Utrecht, Netherlands), R. Kypta (University of California,
San Francisco, San Francisco, CA), and R. Agami (Netherlands Cancer
Institute, Amsterdam, Netherlands). pcDNA3-RanBP3-b wt and pcDNA3-
RanBP3-b wv mutants were constructed by generating a blunt NdeI–
EcoRV fragment from pET14b-h–RanBP3-b wt and wv mutants and by insert-
ing these fragments into the EcoRV site of pcDNA3 (Invitrogen). shRNAs
were expressed from the pSUPER vector (Brummelkamp et al., 2002).
The successful 19-nt target sequences were as follows: RanBP3 2 (AAG-
GCGGAGAAGATTCTGACA), 3 (AAAGAGCCCCAGAAAAATGAG), 4
(AAGAGCCCCAGAAAAATGAGT), 8 (AAGCCGACATGGAGAATG-
CTG), 9 (AACCGCAACGAACTATTTCCT), and 12 (AAGGACACAG-
GTCAGTTGTAT). pSUPER-GFP was a gift from S. Nijman (Netherlands
Cancer Institute), and pBS(SK-)-Daxin-Myc was a gift from R. Nusse
(Stanford University, Stanford, CA). For X. laevis injection studies, we
used HA– -catenin (Funayama et al., 1995) and  -galactosidase in
pCS2  (gift from R. Rupp, Adolph Butenardt Institute, Munich, Ger-
many). pCS2   MT–RanBP3 wt and wv mutants were constructed by in-
serting PCR fragments into the EcoRI and XbaI sites of pCS   Myc.
mRFP– GSK3– -catenin was constructed by inserting a BamHI–SacII–
digested PCR fragment spanning the ORF derived from pRK5-SK-catenin-
GSK (a gift from R. Nusse) into the BglII and SacII sites of mRFP (Camp-
bell et al., 2002).
Cell culture, transfection, and reporter assays
Cells were cultured in DME or in RPMI (NCI-H28) supplemented with 10%
fetal calf serum and penicillin/streptomycin (GIBCO BRL) and were trans-
fected using Fugene 6 (Roche) as instructed by the manufacturer. For
reporter assays, cells were cultured in 12-well plates and transfected
with 100 ng TOP/FOP-Tk-luc, 0.5 ng pRL-CMV, 10 ng Wnt1, 30 ng GFP–
 -catenin, 20 (HEK293) or 100 (NCI-H28) ng  GSK3– -catenin, 100 ng
GFP-CRM1, and 100 ng RanBP3 wt/mutant or as indicated. Luciferase
activity was measured 48 h after transfection using the Dual-luciferase
reporter assay system (Promega). Reporter assays using shRNAs were
performed as the aforementioned reporter assays using 200 ng shRNA
constructs, and luciferase activity was measured 72 h after transfection.
HCT116 cells were grown to 50% confluency in 10-cm dishes and trans-
fected with 5  g of  -galactosidase or RanBP3 wt or wv mutant expres-
sion constructs and 0.5  g EGFP-N3 plasmid to select for transfected
cells. 40 h after transfection, GFP-positive cells were collected using flow
cytometry. Cells were lysed in sample buffer, and 200,000 cells were
resolved on a 10% SDS-PAGE gel and analyzed by Western blotting.
Protein expression and purification
GST, GST-ARM (amino acids 144–665), and GST– -catenin (Wiechens
and Fagotto, 2001) were expressed in Escherichia coli strain BL21-pLysS
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8.7% glycerol, and 2.5 mM 2-mercaptoethanol supplemented with Com-
plete protease inhibitor cocktail tablets (Roche). GST– -catenin fusion
proteins were purified from postribosomal supernatants using protein
G–Sepharose (GE Healthcare). His-tagged Ran RanQ69L, RanBP1, and Ran-
GAP were expressed as previously described (Izaurralde et al., 1997;
Englmeier et al., 2001). 6  His-tagged RanBP3a/b wt and wv mutant
proteins were gifts from L. Englmeier and I. Mattaj (European Molecular
Biology Laboratory, Heidelberg, Germany).
Western blotting
Proteins were analyzed by SDS-PAGE (25  g per lane) and Western
blotting using Immobilon-P transfer membrane (Millipore). Aspecific sites
were blocked with 5% nonfat milk at RT for 1 h. Primary antibodies were
incubated in 1% nonfat milk overnight at 4 C or 1–3 h at RT in the follow-
ing dilutions:  -catenin, 1:5,000; ABC, 1:500; RanBP3, 1:5,000; TCF4,
1:500; 414, 1:1,000; tubulin, 1:20; actin, 1:5,000; and c-Myc, 1:1,000.
Blots were washed with PBS/0.05% Tween 20. Enhanced chemilumines-
cence (GE Healthcare) was used for detection of proteins.
Immunofluorescence and confocal microscopy
SW480 and DLD1 cells were transfected with 600 ng RanBP3 per six
wells using Fugene 6. 45 h after transfection, cells were fixed for 10 min
in 3.7% formaldehyde in PBS, permeabilized for 5 min in 0.2% Triton/
PBS, and incubated for 1 h at RT with primary antibodies diluted in 0.05%
BSA/PBS. Cells were washed in PBS, incubated in fluorescently conju-
gated secondary antibody (Invitrogen), and mounted in Vectashield (Vec-
tor Laboratories). Images were recorded using a confocal microscope
(NT; Leica). HEK293 cells were transfected with 40 ng mRFP–GSK3–
 -catenin, 200 ng RanBP3, and/or 200 ng GFP-Rev-NES per six wells us-
ing Fugene 6. After 40 h, cells were either treated or not treated with 50
nM LMB for 1 h. Cells were fixed for 10 min in 3.7% formaldehyde in PBS
and mounted in Vectashield. In each condition, cells with equally low ex-
pression were recorded with a confocal microscope (TCS SP2 AOBS; Leica).
Nuclear and cytoplasmic regions of confocal images were quantified and
background subtracted, and nuclear/cytoplasmic ratios were calculated
using Image J software.
In vitro binding studies
In pull-down assays, 750 pmol GST, GST– -catenin, or GST-ARM were in-
cubated for 1 h at 4 C with X. laevis extracts (Hetzer et al., 2000) and
1:1 diluted in 200 mM NaCl, 20 mM Hepes-KOH, pH 7.9, 8.7% glyc-
erol, and 2.5 mM 2-mercaptoethanol (buffer A). RanQ69L was added at
2   M. In binding assays using HeLa nuclear extracts (4C Biotech),
RanQ69L was used at 1  M. Proteins were eluted with buffer A supple-
mented with 300 mM NaCl. After TCA precipitation, proteins were ana-
lyzed by Western blot. Pull-down assays using all recombinant proteins
were performed by incubating for 1 h at 4 C; 1.5  M GST– -catenin
beads with 0.2, 0.5, or 2  M wt or wv mutant RanBP3 and 2  M RanGTP
in PBS, 8.7% glycerol, and 2 mM MgCl2. Proteins were eluted with 500
mM NaCl, 8.7% glycerol, 2 mM MgCl2, and 2.5 mM 2-mercaptoethanol
in the presence or absence of RanBP1 or RanGAP in PBS and prepared
for analysis on SDS-PAGE.
Cell fractionation
For cell fractionation, we used the protocol of Andrews and Faller (1991)
with the following adaptations. Cells and nuclei were spun down at 4 C
for 3 min at 500 and 300 g, respectively. 10 mM NaF, 2 mM NaVO3,
and protease inhibitors (Complete protease inhibitor cocktail tablets minus
EDTA) were added to the lysis buffers. After incubation in hypotonic
buffer, NP-40 was added at a concentration of 10% and samples were
vortexed shortly and passed through a 25G needle. Whole cell extracts
were reconstituted by mixing nuclear and cytosolic extracts.
X. laevis injection studies
mRNAs were synthesized in vitro using SP6 polymerase (Promega). mRNAs
were injected in the subequatorial region of a dorsal or ventral blastomere
at the four-cell stage as described previously (Fagotto et al., 1996, 1997).
Embryos were raised in 0.1  MBSH (88 mM NaCl, 1 mM KCl, 2.4 mM
NaHCO3, 0.82 mM MgSO4, 0.33 mM Ca[NO3]2, 0.41 mM CaCl2, 10
mM Hepes, pH 7.4, 10 mg/ml benzylpenicillin, and 10 mg/ml streptomy-
cin) until tail bud stage and scored. RNA was prepared from late stage 9
embryos as previously described (Schohl and Fagotto, 2003).
dsRNA synthesis D. melanogaster
 -galactosidase, Daxin, and RanBP3 dsRNAs were synthesized according
to Kennerdell and Carthew (1998) and purified using S400 Spin Columns
(GE Healthcare). PCR products were verified by DNA sequencing. For D.
melanogaster RanBP3 dsRNA, two 750-bps fragments that span exon-2 of
the D. melanogaster RanBP3 gene (GC10225) were amplified from ge-
nomic DNA. Fragment 1 spans the RanBP3 ORF from position 341–1104,
and fragment 2 from position 683 to 3 UTR position 1423. The following
primers were used: BP3 sense primer 1 (AGAACAACATGCCAAATGT-
TCAG), BP3 antisense primer 1 (GACGCCGTTTTTCGCTTCCTCT), BP3
sense primer 2 (AGAAACGCAAATACGAGGAGGT), and BP3 antisense
primer 2 (GGCGCGCTTTATTAATTAGTGT). pBS(SK-)-Daxin-Myc (Willert
et al., 1999) was used as a template to generate a 750-bp dsRNA Daxin
fragment spanning nucleotides 1462–2210. The following primers were
used: Daxin sense primer (GAGAAGTTTGCACTGGACGAAGA) and
Daxin antisense primer (GGCTTGACAAGACCCATCGCTT). For  -galac-
tosidase dsRNA, nucleotides spanning from 1296 to 1921 of the lac op-
eron (available from GenBank/EMBL/DDBJ under accession no. J01636)
were subcloned into pGEMT-easy and T7 RNA polymerase promoters
were added by PCR of the linearized plasmid.
Cuticle analysis and immunohistochemistry
Embryos were prepared for injections as previously described (Kennerdell
and Carthew, 1998) with minor modifications. Embryos were injected
with 3  M dsRNA, and for RanBP3 RNAi, a 1:1 mixture of two dsRNA
fragments was used. After injection, the embryos were covered with oil
and incubated for 48 h at 18 C in a humidified chamber. After incuba-
tion, the embryos were manually dissected from their viteline membranes
and incubated overnight at 65 C in glycerol/acetic acid (1:3). The next
day, embryos were mounted in Hoyers mounting medium and incubated
for 1–2 d at 55 C and visualized by dark field microscopy. For anti-
Engrailed antibody staining, embryos were incubated for 15 h, fixed,
manually devitalinized, and processed for antibody staining according to
standard procedures (Patel, 1994).
D. melanogaster RT-PCR
Dechorionated wt embryos were injected with buffer or RanBP3 dsRNA
and then aged at 16 C for 15 h. RNA was prepared and treated with
DNase (RNA-Easy kit; QIAGEN), and randomly primed first-strand cDNA
was prepared using SuperScript kit (Invitrogen), both according to the
manufacturer’s protocol. Samples for the RP49-specific control PCRs were
initially diluted 80-fold to compensate for higher expression levels. Subse-
quently, a series of twofold dilutions was performed for each sample; 1  l
of each dilution was used in a PCR reaction. Primers were chosen to span
an intron to allow discrimination of PCR products originating from contam-
inating genomic DNA from those originating from first-strand cDNA. Prim-
ers used were as follows: RanBP3 forward (AGTGACAGCGATAACA-
CAGCGATAA) and reverse (GCAGAAACGGATTATTCAGCAGG) and
RP49 forward (ATGACCATCCGCCCAGCA) and reverse (TTGGGGTTG-
GTGAGGCGGAC). 30-cycle PCRs were performed using SuperTaq Plus
polymerase (SpheroQ), and equal volumes of the reaction products
were electrophoresed on 1.5% agarose gels and visualized by ethidium
bromide staining.
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